Analysis of time sequence of CD20 antigen expression changes on tumor cells following exposure to cytokines.

被引：0
作者：
Hari, P [1 ]
Venugopal, P [1 ]
Sivaraman, S [1 ]
Gladstone, B [1 ]
Dutt, D [1 ]
Preisler, H [1 ]
机构：
[1] Rush Canc Inst, Chicago, IL USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4634
引用
收藏
页码：228B / 229B
页数：2
相关论文
共 39 条
  • [11] FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20
    Hübl, W
    Iturraspe, J
    Braylan, RC
    [J]. CYTOMETRY, 1998, 34 (02): : 71 - 74
  • [12] Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells
    D'Arena, Giovanni
    Ruggieri, Vitalba
    D'Auria, Fiorella
    La Rocca, Francesco
    Simeon, Vittorio
    Statuto, Teodora
    Caivano, Antonella
    Telesca, Donatella
    Del Vecchio, Luigi
    Musto, Pellegrino
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (08) : 2458 - 2459
  • [13] CD20 (Pan-B cell antigen) expression on bone marrow-derived T cells
    Algino, KM
    Thomason, RW
    King, DE
    Montiel, MM
    Craig, FE
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 106 (01) : 78 - 81
  • [14] Transient expression of CD20 antigen (pan B cell marker) in activated lymph node T cells
    Murayama, Y
    Mukai, R
    Sata, T
    Matsunaga, S
    Noguchi, A
    Yoshikawa, Y
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 1996, 40 (06) : 467 - 471
  • [15] Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms
    Wojciechowski, W
    Li, HF
    Marshall, S
    Dell'Agnola, C
    Espinoza-Delgado, I
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (12) : 7859 - 7868
  • [16] Development of a novel humanized anti-CD20 chimeric antigen receptor; Effect on the CD20 down-regulated and mAb therapy resistant tumor cells
    Watanabe, Keisuke
    Terakura, Seitaro
    Uchiyama, Susumu
    Shimada, Kazuyuki
    Tomita, Akihiro
    Nishida, Tetsuya
    Murata, Makoto
    Naoe, Tomoki
    Kiyoi, Hitoshi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S217 - S217
  • [17] Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells
    Xu, Yingxi
    Li, Saisai
    Wang, Ying
    Liu, Jia
    Mao, Xinhe
    Xing, Haiyan
    Tian, Zheng
    Tang, Kejing
    Liao, Xiaolong
    Rao, Qing
    Xiong, Dongsheng
    Wang, Min
    Wang, Jianxiang
    [J]. HUMAN GENE THERAPY, 2019, 30 (04) : 497 - 510
  • [18] Structural changes in the internal domain of CD20 antigen associated with the emergence of rituximab resistance: Effects of proteasome inhibition in CD20 structure and rituximab anti-tumor activity in rituximab-resistant cell lines (RRCL).
    Hernandez-Ilizaliturri, FJ
    Olejniczak, SH
    Knight, J
    Czuczman, MS
    [J]. BLOOD, 2005, 106 (11) : 425A - 425A
  • [19] Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
    Aue, Georg
    Lindorfer, Margaret A.
    Beum, Paul V.
    Pawluczkowycz, Andrew W.
    Vire, Berengere
    Hughes, Thomas
    Taylor, Ronald P.
    Wiestner, Adrian
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 329 - 332
  • [20] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    [J]. LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
1234